Company Description
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation.
It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.
In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement.
The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017.
ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Country | United States |
Founded | 2002 |
IPO Date | Nov 15, 2007 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 29 |
CEO | Paul F. Hickey |
Contact Details
Address: 1001 Calle Amanecer San Clemente, California 92673 United States | |
Phone | (949) 429-6680 |
Website | reshapelifesciences.com |
Stock Details
Ticker Symbol | RSLS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001371217 |
CUSIP Number | 761123603 |
ISIN Number | US76090R2004 |
Employer ID | 48-1293684 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Dan W. Gladney | Executive Chair |
Paul F. Hickey | Chief Executive Officer, President and Director |
Thomas Stankovich | Senior Vice President and Chief Financial Officer |
Dr. Mark B. Knudson Ph.D. | Co-Founder and Special Advisor to the Chief Executive Officer |
Dr. Katherine S. Tweden Ph.D. | Co-Founder |
Al Diaz | Vice President of Operations and Research & Development |
Dr. Dov Gal D.V.M., M.B.A. | Vice President of Regulatory Clinical Quality and Compliance Officer |
Jody B. Dahlman | Director of Communications |
Naqeeb A. Ansari | Senior Vice President of Global Commercial Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |
Jun 25, 2021 | EFFECT | Notice of Effectiveness |